Several seminal randomized trials established the standard of L+ radiation therapy (RT) in the treatment of early stage BC. More recently, interpretation of results from trials on older women suggests that breast RT may be omitted in ER+, stage T1N0 BC patients >70 years of age who receive adjuvant endocrine therapy (ET). The purpose of this study is to examine the practice trends of adjuvant ET+RT dual therapy (DT), RT alone, and ET alone after L in older women with ER+ BC, and further evaluate clinical outcomes by type of adjuvant therapy administered. In the 2003 to 2014 National Cancer Database, we identified 81,907 women age ≥70 years with T1N0, ER+BC who underwent L and had a minimum one year follow-up. Women who received no adjuvant therapy and those receiving any chemotherapy were excluded. We performed Chi-square tests to compare frequency of the 3 different adjuvant treatments administered, and the NCI Joinpoint Regression Program (Ver. 4.6.0.0) to estimate average annual percentage change in the utilization rates of the 3 different adjuvant treatments. Patients were stratified by Charlson-Deyo Comorbidity (CDC) score to be healthy (score 0) vs. with co-morbid status (CDC ≥1). Kaplan-Meier statistics and a Cox proportional hazards model adjusted for age, CDC score, and demographic variables (race/ethnicity, insurance, facility type, median neighborhood income, residence, and distance from hospital) were used to compare overall survival (OS) between patients receiving adjuvant DT, RT alone, and ET alone. Trending the utilization rates of the 3 different adjuvant treatments from 2003 to 2014, we observed the practice of adjuvant DT increase from 59.8% to 63.2%, RT alone decrease from 28.8% to 11.8%, and ET alone increase from 11.4% to 25% (p<0.0001). On Joinpoint regression analysis, the rate of RT alone declined by 8.2% annually (95% CI 7.1-9.4%, p<0.0001), whereas ET alone increased by an average of 8.0% per year (95% CI 6.1-10.0%, p<0.0001). Stratification by healthy and comorbid status noted a similar change in practice trends within each cohort. The overall median age of our study population is 76 years (IQR 72-80). Median follow-up is 57.5 months. The 5-year overall survival is 89.8%, 84.9%, and 79.2% for adjuvant DT, RT alone, and ET alone, respectively (p<0.0001). After adjusting for age, comorbidities, and demographic variables we note that compared to adjuvant DT, the hazard of death with RT alone is 20.3% (p<0.0001), and with ET alone is 44.3% (p<0.0001). In this study we observed a steady decline in the utilization of adjuvant RT alone and an increase in ET alone. Compared to adjuvant DT, the hazard of death was higher in patients receiving ET alone compared to RT alone. When considering de-escalation of therapy in older patients, our data suggests that older women derive benefit from adjuvant RT. These observations warrant further comparative study of RT alone vs. ET alone for defining the optimal adjuvant monotherapy in older women.